Abstract Fahr-type calcification is a relatively common finding in the elderly, and in younger patients with Alzheimer's disease, calcification in the basal ganglia is not uncommon. However, as far as we know, an immunohistochemical study of intracranial calcification in neurodegenerative diseases has not been performed. In this study, we examined intracranial calcification of the basal ganglia and cerebellum with antibodies against noncollagenous bone matrix proteins. Nineteen brains were employed. The diagnoses were diffuse neurofibrillary tangles with calcification in five, Alzheimer's disease in five, Pick's disease in one, progressive supranuclear palsy in one, Parkinson's disease in one, and six controls. By conventional histology, three patterns of calcium (Ca) deposition were recognized: diffuse deposition within the tunica media of small and medium-sized vessels (type 1 deposition), free spherical or lobulated concretions (type 2 deposition) in the parenchyma, and rows of small calcospherites lying along capillaries (type 3 deposition). Type 3 deposition is relatively rare, and may be a hallmark of severe intracranial calcification. Immunohistochemistry demonstrated that osteopontin was present diffusely in all Ca deposition types. Osteocalcin was present chiefly in the peripheral region of type 2 and 3 depositions, as well as in only the rims of type 1 deposition. Bone sialoprotein and osteonectin were found only in the core portions of type 2 and 3 depositions. In brief, type 1 deposition shows a different staining pattern from type 2 and 3. Different Ca deposition patterns of noncollagenous bone matrix proteins may suggest their separate roles in the pathogenesis of intracranial calcification.
Introduction
Intracranial calcification can occur under physiological and pathological conditions. A mild calcification in the blood vessels, the pineal body and the choroid plexus is a common incidental finding in elderly brains. The most common form of symmetrical intracranial calcification is that which occurs in the choroid plexus [23] . Fahr-type calcification (striatopallidodentate calcification) is also a relatively common finding, and affects as many as 1-2% of patients undergoing diagnostic neuroimaging [4, 6, 23] . In most cases, it is an incidental finding [6] . Because of its lack of specificity, it has been suggested that Fahr-type calcification cannot explain common neurological disturbances in the majority of cases [6, 14] . However, in diffuse neurofibrillary tangles with calcification (DNTC), Fahrtype calcification is thought to be one of the most characteristic features. DNTC is a rare form of slowly progressive dementia characterized by frontotemporal atrophy, neurofibrillary tangles (NFTs) and Fahr-type calcification without senile plaques [11, 12, 20, 24] . It is also reported that calcification in the basal ganglia is not rare in younger patients with Alzheimer's disease (AD) [15] . However, as far as we know, an immunohistochemical study of intracranial calcification in neurodegenerative diseases, including AD and DNTC, has not been performed.
In this study, we examined intracranial calcification of basal ganglia and cerebellum in neurodegenerative diseases, including AD and DNTC, with antibodies against noncollagenous bone matrix proteins. Osteopontin (OPN), osteocalcin (OC), osteonectin (ON) and bone sialoprotein (BSP) are major noncollagenous bone matrix proteins. However, their roles in the pathogenesis of intracranial calcification have never been examined, and their distribution patterns in calcified lesions in the basal ganglia and cerebellum have not been clarified.
Materials and methods

Materials
Nineteen brains with calcification in the basal ganglia were employed in this study ( Table 1) . The diagnoses were DNTC in five patients (57.4±10.9 years, three females and two males), AD in five (68.0±13.4 years, four females and one male), Pick's disease (PiD) in one (82 years, female), progressive supranuclear palsy (PSP) in one (68 years, male), Parkinson's disease (PaD) in one (79 years, male), and controls without neurological diseases (62.5±10.0 years, four females and two males). All neurological cases were sporadic. In each patient, the diagnosis was confirmed histopathologically.
Histology and immunohistochemical assays
The brains were formalin-fixed, and 6-µm-thick paraffin-embedded sections were prepared and stained for observation with a light microscope using hematoxylin-eosin and von-Kossa silver staining. After confirmation of calcification with the von-Kossa method, the same blocks were re-cut, and immunohistochemical assays were performed.
For the immunohistochemistry, we used following primary antibodies (Abs): anti-OPN Ab (10A16; mouse, monoclonal; IBL, Japan; 1:100), anti-OC Ab (rabbit, polyclonal; BTI, USA; 1:25), anti-ON Ab (AON-1; mouse, monoclonal; ARP, USA; 1:50), anti-BSP Ab (mouse monoclonal; Chemicon, USA; 1:1,000).
Deparaffinized sections were incubated with 1% H 2 O 2 in methanol for 30 min to eliminate endogenous peroxidase activity in the tissue. At least, three sections for each primary antibody were cut from the same block: one was pretreated for 5 min with formic acid (FA, 99%; Sigma, USA), one was heated in a microwave oven (MW) for 10 min at 90°C, and the other was used without pretreatment. After blocking with 10% normal serum, sections were incubated overnight at 4°C with one of the primary antibodies in 0.05 M TRIS-HCl buffer, pH 7.2, containing 0.1% Tween and 15 mM NaN 3 . After three 10-min washes in PBS, sections were incubated in biotinylated anti-mouse or anti-rabbit secondary antibody for 1 h, and then in avidin-biotinylated horseradish peroxidase complex (ABC Elite kit, Vector Laboratories, USA) for 1 h. The reaction was visualized with 0.2% 3,3'-diaminobenzidine in 50 mM TRIS-HCl buffer, pH 7.4, containing 0.003% H 2 O 2 . Counterstaining was carried out with hematoxylin.
Results
Conventional histology
Calcium deposition in the basal ganglia was found in all 19 brains, although deposition in the cerebellum were found only in 6 brains (DNTC5/5, AD0/5, controls1/6) ( Table 2) .
Three patterns of calcium deposition were recognized: diffuse deposition within the tunica media of small and medium-sized vessels (type 1 deposition) (Fig. 1a) , free spherical or lobulated concretions in the parenchyma (type 2 deposition) (Fig. 1b) , and rows of small calcospherites lying along capillaries (type 3 deposition) (Fig. 1c) . Most depositions of type 2 are 5-10 µm in diameter and are scattered in the parenchyma, while most depositions of type 3 are less than 5 µm in their diameters and form rows of small calcospherites lying along capillaries. In most cases, it is not difficult to distinguish type 2 from type 3.
Type 1 deposition was recognized in all 19 brains, while type 2 deposition was found in 14 (DNTC 5/5, AD 4/5, Immunostaining profile of calcium deposition: OPN In type 1 deposition, anti-OPN Ab stained Ca depositions with a small granular pattern without pretreatment (Fig. 2a) , and MW pretreatment enhanced its immunoreactivity, especially in the rims of Ca depositions (Fig. 2b) .
In type 2 and type 3 deposition, anti-OPN Ab stained Ca depositions positively without pretreatment (Fig. 2c) . MW pretreatment attenuated its immunoreactivity in the core portions, but enhanced it in the peripheral rims (Fig. 2d) . FA pretreatment showed little or no enhancement on the immunoreactivity in all type depositions. The immunostaining profile of Ca deposition with anti-OPN Ab was similar for all brains.
Immunostaining profile of calcium deposition: OC, ON, BSP After MW pretreatment, anti-OC Ab stained almost all type 2 and type 3 depositions. Many Ca depositions were stained by anti-OC Ab with enhanced immunoreactivity of the peripheral region (Fig. 2f, g ), but some were stained with enhanced immunoreactivity of the core region. In type 1 deposition, only the rims of Ca depositions were recognized by anti-OC Ab (Fig. 2e) . Without MW pretreatment, the immunoreactivity of OC was weak in all type depositions, and FA pretreatment attenuated its immunoreactivity. Anti-ON Ab and anti-BSP Ab showed a similar staining profile. Type 1 deposition were not stained by anti-ON Ab or anti-BSP Ab, even after FA or MW pretreatment. Only core portions of type 2 and type 3 depositions were recognized by anti-ON Ab (Fig. 2j, k) and anti-BSP Ab (Fig. 2h, i) . FA pretreatment enhanced their immunoreactivity, but MW pretreatment attenuated them. The immunostaining profile of Ca deposition with these antibodies was similar for all brains.
Discussion
Immunostaining pattern of OPN, OC, ON, BSP
OPN is an acidic glycoprotein of about 41 kDa originally found in bone matrix and subsequently in kidney, placenta, and blood vessels [2, 18] . Although not much is known about its function, the OPN level is elevated during wound healing and inflammation in most tissues studied to date [8] . Several studies of OPN expression in the central nervous system have been reported. In rat brain, transient up-regulation of OPN mRNA in the hippocampus following ischemia and delayed expression of OPN after focal stroke have been demonstrated [13, 26] . In human brain, the association of OPN with ischemic axonal death in periventricular leukomalacia has been suspected [22] . However, a study of OPN expression in intracranial MW pretreatment enhanced its immunoreactivity, especially in the rim of Ca deposition (b). In type 2 and type 3 depositions, anti-OPN Ab stained Ca deposition without pretreatment (c). MW pretreatment attenuated its immunoreactivity in the core portion, but enhanced it in the peripheral rim (d). After MW pretreatment, anti-OC Ab stained almost all of type 2 and type 3 depositions positively (f, g). In type 1 deposition, only a rim of Ca deposition was recognized by anti-OC Ab (e). Only core portions of type 2 and type 3 depositions were recognized by anti-ON Ab (j, k) and anti-BSP Ab (h, i), especially after formic acid pretreatment. a-e Patient 5, cerebellum; f, h, j patient 4, cerebellum; g patient 19, cerebellum; i, k patient 8, globus pallidus (OPN osteopontin, OC osteocalcin, ON osteonectin, BSP bone sialoprotein, MW microwave, Ab antibody). Bars a-g 50 µm, h-k 20 µm calcification of human brains has not been performed. In this study, we showed that OPN was present diffusely in all Ca depositions, which suggests that OPN plays an important role in intracranial calcification in its early to late stages.
OC is secreted by osteoblasts and exhibits high affinity for calcium, phospholipid, and hydroxyapatite [17] . OC is abundant in the extracellular matrix of mineralized tissues [10] . However, the absence of OC in very early calcification stages, but its presence after calcified deposits were formed, suggests that OC is not necessary for initiation of arterial calcification [7] . OC promotes bone resorption and is thought to play an important role in the formation and remodeling of mineralizing tissues [21] . In this study, we showed that OC was present in type 2 and type 3 depositions, frequently in the peripheral regions, as well as in the rims of type 1 depositions. These results suggest that OC plays its role in the late stage of intracranial calcification in the basal ganglia and cerebellum.
BSP is essentially unique to hydroxyapatite crystals [5, 16] . BSP, which is expressed in association with the initial mineralization of bone matrix [3, 27] , can nucleate apatite formation from physiological concentrations of Ca 2+ and PO 4 3- [9] and is therefore a candidate protein for the initiation of apatite crystal formation during bone formation de novo [28] . In this study, BSP was found in the core portions of type 2 and type 3 depositions. Therefore, BSP may be a nucleator of hydroxyapatite in intracranial calcification, at least in type 2 and 3 deposition.
ON, a 38-kDa acidic glycoprotein with high interspecies homology, is also known as SPARC (secreted protein acidic and rich in cysteine). ON is one of the major bone matrix proteins and has been shown to promote binding of calcium to collagen [25] , thus suggesting a role in Ca deposition. ON can inhibit hydroxyapatite crystal formation [19] . This role seems to prevent excessive mineralization in bone [1] . In this study, ON was also found in the core portions of type 2 and type 3 depositions. This may suggest that ON, as well as BSP, is a nucleator of hydroxyapatite in intracranial calcification, at least in type 2 and 3 deposition.
It is not easy to identify the types of cerebral cell that are able to synthesize the different noncollagenous bone matrix proteins. However, BSP and ON were present only in type 2 and 3 depositions. Therefore, it is possible that parenchymal cells rather than vascular cells produced them.
Differences of calcium deposition among various diseases
The immunostaining profile of Ca deposition with antibodies against bone matrix proteins was similar for all brains. However, the types of Ca deposition in various diseases were somewhat different. In DNTC, all three types of Ca deposition were always found. In other conditions, type 1 deposition was identified in all 14 brains, while type 2 was in 9 (AD 4/5, PiD 0/1, PSP 1/1, PaD 1/1, controls 3/6) and type 3 in 4 (AD 2/5, PiD 0/1, PSP 0/1, PaD 0/1, controls 2/6).
In summary, type 1 deposition was found in all 19 brains, while type 2 was in 14 and type 3 in 9. All 9 brains with type 3 deposition also had type 2 deposition. This result suggests that the calcification of hyalinized vessels (type 1 deposition) could be merely an accessory finding in neurodegenerative diseases. Type 2 and type 3 deposition might reflect the severity of intracranial calcification. Type 3 deposition is pervasive in DNTC, but relatively rare in other conditions. Type 3 deposition may be a hallmark of severe intracranial calcification.
Immunostaining pattern of calcium deposition: differences among type l, type 2 and type 3 depositions
In type 1 deposition, ON and BSP were not found, and anti-OC Ab stained only the rims of Ca depositions, while in type 2 and 3 depositions, ON and BSP were frequently identified in the core regions of Ca depositions, and anti-OC Ab stained almost all Ca depositions. In brief, type 1 deposition shows a somewhat different staining pattern from those of type 2 and type 3 depositions.
In type 2 and 3 depositions, OPN showed diffuse positive staining without pretreatment, but MW pretreatment attenuated its immunoreactivity in the core regions and enhanced its immunoreactivity in the peripheral regions. ON and BSP were found only in the core regions. The core regions in type 2 and type 3 depositions were different from peripheral regions in their staining pattern.
Conclusion
Three patterns of Ca deposition were recognized: diffuse deposition within the tunica media of small and mediumsized vessels (type 1 deposition), free spherical or lobulated concretions (type 2 deposition), and rows of small calcospherites lying along capillaries (type 3 deposition). OPN was diffusely present in all of the Ca depositions, while OC was present in type 2 and type 3 deposition, frequently in the peripheral regions, as well as in the rims of type 1 depositions. BSP and ON were found in the core portions of type 2 and type 3 depositions. Type 1 deposition shows a different staining pattern from those of type 2 and type 3 depositions, and type 3 deposition may be a hallmark of severe intracranial calcification. Different Ca deposition patterns of noncollagenous bone matrix proteins may suggest their separate roles in the pathogenesis of intracranial calcification.
